Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Rupak Mukherjee and Francis Spinale.
Rupak Mukherjee
Connection Strength
7.110
Francis Spinale
  1. Cardiac function and circulating cytokines after endotoxin exposure in neonatal mice. Pediatr Res. 2010 Nov; 68(5):381-6.
    View in: PubMed
    Score: 0.393
  2. Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. J Surg Res. 2012 Jan; 172(1):59-67.
    View in: PubMed
    Score: 0.384
  3. Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation. 2010 Jul 06; 122(1):20-32.
    View in: PubMed
    Score: 0.383
  4. Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury. FASEB J. 2010 Oct; 24(10):3819-28.
    View in: PubMed
    Score: 0.383
  5. Short-term disruption in regional left ventricular electrical conduction patterns increases interstitial matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H217-24.
    View in: PubMed
    Score: 0.381
  6. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg. 2008 Oct; 86(4):1268-76.
    View in: PubMed
    Score: 0.340
  7. Protein kinase C isoform activation and endothelin-1 mediated defects in myocyte contractility after cardioplegic arrest and reperfusion. Circulation. 2006 Jul 04; 114(1 Suppl):I308-13.
    View in: PubMed
    Score: 0.291
  8. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5):H2216-28.
    View in: PubMed
    Score: 0.290
  9. Myocyte contractility with caspase inhibition and simulated hyperkalemic cardioplegic arrest. Ann Thorac Surg. 2004 May; 77(5):1684-9; discussion 1689-90.
    View in: PubMed
    Score: 0.251
  10. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
    View in: PubMed
    Score: 0.230
  11. Effects of adrenomedullin on human myocyte contractile function and beta-adrenergic response. J Cardiovasc Pharmacol Ther. 2002 Oct; 7(4):235-40.
    View in: PubMed
    Score: 0.225
  12. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
    View in: PubMed
    Score: 0.124
  13. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med. 2014 Feb 12; 6(223):223ra21.
    View in: PubMed
    Score: 0.123
  14. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014 Mar 01; 7(2):340-50.
    View in: PubMed
    Score: 0.123
  15. Cyclosporin A in left ventricular remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2014 Jan 01; 306(1):H53-9.
    View in: PubMed
    Score: 0.121
  16. Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
    View in: PubMed
    Score: 0.118
  17. Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7.
    View in: PubMed
    Score: 0.113
  18. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.107
  19. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.103
  20. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol. 2011 Oct; 301(4):H1656-66.
    View in: PubMed
    Score: 0.103
  21. Continuous localized monitoring of plasmin activity identifies differential and regional effects of the serine protease inhibitor aprotinin: relevance to antifibrinolytic therapy. J Cardiovasc Pharmacol. 2011 Apr; 57(4):400-6.
    View in: PubMed
    Score: 0.101
  22. Hemodynamics and myocardial blood flow patterns after placement of a cardiac passive restraint device in a model of dilated cardiomyopathy. J Thorac Cardiovasc Surg. 2011 Nov; 142(5):1038-45.
    View in: PubMed
    Score: 0.101
  23. Heterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function. Am J Physiol Heart Circ Physiol. 2010 Dec; 299(6):H1947-58.
    View in: PubMed
    Score: 0.098
  24. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010 Sep 24; 285(39):30316-27.
    View in: PubMed
    Score: 0.096
  25. Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants. J Thorac Cardiovasc Surg. 2010 Dec; 140(6):1257-65.
    View in: PubMed
    Score: 0.096
  26. Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. Ann Thorac Surg. 2010 Jun; 89(6):1843-52; discussion 1852.
    View in: PubMed
    Score: 0.095
  27. Interstitial plasmin activity with epsilon aminocaproic acid: temporal and regional heterogeneity. Ann Thorac Surg. 2010 May; 89(5):1538-45.
    View in: PubMed
    Score: 0.095
  28. Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms. J Cardiovasc Pharmacol. 2010 Apr; 55(4):408-16.
    View in: PubMed
    Score: 0.094
  29. Temporally and regionally disparate differences in plasmin activity by tranexamic acid. Anesth Analg. 2010 Mar 01; 110(3):694-701.
    View in: PubMed
    Score: 0.094
  30. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail. 2009 Jul; 2(4):351-60.
    View in: PubMed
    Score: 0.089
  31. Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model. Anesth Analg. 2009 Feb; 108(2):399-406.
    View in: PubMed
    Score: 0.087
  32. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1394-402.
    View in: PubMed
    Score: 0.084
  33. Differential effects of protein kinase C isoform activation in endothelin-mediated myocyte contractile dysfunction with cardioplegic arrest and reperfusion. Ann Thorac Surg. 2006 Aug; 82(2):664-71.
    View in: PubMed
    Score: 0.073
  34. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol. 2006 Feb; 47(2):228-35.
    View in: PubMed
    Score: 0.071
  35. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
    View in: PubMed
    Score: 0.070
  36. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation. 2005 Aug 30; 112(9 Suppl):I242-8.
    View in: PubMed
    Score: 0.069
  37. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.066
  38. Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Mar; 129(3):584-90.
    View in: PubMed
    Score: 0.066
  39. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation. 2005 Mar 08; 111(9):1166-74.
    View in: PubMed
    Score: 0.066
  40. Caspase inhibition attenuates contractile dysfunction following cardioplegic arrest and rewarming in the setting of left ventricular failure. J Cardiovasc Pharmacol. 2004 Dec; 44(6):645-50.
    View in: PubMed
    Score: 0.065
  41. Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation. 2004 Sep 14; 110(11 Suppl 1):II268-73.
    View in: PubMed
    Score: 0.064
  42. A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2004 Feb; 18(1):25-9.
    View in: PubMed
    Score: 0.062
  43. Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg. 2003 Dec; 76(6):2054-61; discussion 2061.
    View in: PubMed
    Score: 0.061
  44. Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1892-9.
    View in: PubMed
    Score: 0.061
  45. Myocardial remodeling after discrete radiofrequency injury: effects of tissue inhibitor of matrix metalloproteinase-1 gene deletion. Am J Physiol Heart Circ Physiol. 2004 Apr; 286(4):H1242-7.
    View in: PubMed
    Score: 0.061
  46. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003 Oct 07; 108(14):1753-9.
    View in: PubMed
    Score: 0.060
  47. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003 Jun 10; 107(22):2857-63.
    View in: PubMed
    Score: 0.059
  48. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003 Mar; 125(3):602-10.
    View in: PubMed
    Score: 0.058
  49. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003 Feb 07; 92(2):177-85.
    View in: PubMed
    Score: 0.058
  50. Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg. 2002 May; 194(5):603-9.
    View in: PubMed
    Score: 0.055
  51. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arterioscler Thromb Vasc Biol. 2016 Apr; 36(4):636-46.
    View in: PubMed
    Score: 0.036
  52. Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2015 Jun 01; 308(11):H1391-401.
    View in: PubMed
    Score: 0.033
  53. Reply to "letter to the editor: 'cyclosporin A in left ventricular remodeling after myocardial infarction'". Am J Physiol Heart Circ Physiol. 2014 Mar 01; 306(5):H778-9.
    View in: PubMed
    Score: 0.031
  54. Reproducible porcine model of thoracic aortic aneurysm. Circulation. 2013 Sep 10; 128(11 Suppl 1):S186-93.
    View in: PubMed
    Score: 0.030
  55. Pulmonary artery endothelial cell phenotypic alterations in a large animal model of pulmonary arteriovenous malformations after the Glenn shunt. Ann Thorac Surg. 2013 Oct; 96(4):1442-1449.
    View in: PubMed
    Score: 0.030
  56. Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H114-24.
    View in: PubMed
    Score: 0.024
  57. Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation. 2009 Sep 15; 120(11 Suppl):S262-8.
    View in: PubMed
    Score: 0.023
  58. Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol. 2009 Oct; 175(4):1746-56.
    View in: PubMed
    Score: 0.023
  59. Differential effect of wall tension on matrix metalloproteinase promoter activation in the thoracic aorta. J Surg Res. 2010 May 15; 160(2):333-9.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.